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A case of ectopic parathyroid hormone production
by a pulmonary neoplasm
Eric S. Weiss, MD,a John Doty, MD,a Malcolm V. Brock, MD,a Lloyd Halvorson, MD,b
and Stephen C. Yang, MD,a Baltimore and Fredrick, Md
Hypercalcemia is a well-recognized, albeit infrequent,complication of primary bronchogenic carcinoma. Incontrast to neoplasms, which produce hypercalcemiaby means of bony invasion with osteolysis, the cause
of hypercalcemia in bronchogenic carcinoma has convincingly
been demonstrated to be humoral in nature and almost exclusively
associated with parathyroid hormone–related protein (PTH-rp). By
stark contrast, only 3 cases of bronchogenic carcinoma associated
with ectopic production of native parathyroid hormone (PTH) have
been reported.1-3 Here we describe a rare case of a pulmonary
neoplasm producing ectopic PTH. We further report the successful
resection and restoration of normocalcemia in our patient. This
unique case challenges conventional beliefs regarding the diagno-
sis and management of humoral hypercalcemia of malignancy.
Clinical Summary
A 71-year-old white woman presented to her community emer-
gency department with lightheadedness, nausea, and difficulty
with balance and was noted to have a serum calcium level of 18.8
mg/dL. Chest radiography revealed a right lung radiodensity,
further characterized by chest computed tomography as a 2.4 
2.6-cm mass within the right midlung adjacent to the pleura.
Transthoracic needle biopsy revealed non–small cell lung cancer
favoring adenocarcinoma. She was started on calcitonin and
palmidronate for her hypercalcemia and transferred to our tertiary-
care facility for definitive treatment.
At our institution, her PTH level was measured at 288 pg/mL
(normal range, 10-65 pg/mL). Her PTH-rp assay (Quest Diagnos-
tics, San Juan Capistrano, Calif) was less than 0.2 pmol/L (normal,
1.3 pmol/L). Serum phosphate was low at 1.2 mg/dL (normal
range, 2.7-4.5 mg/dL); 1,25 (OH) vitamin D level was increased at
298 pg/mL (normal range, 15-60 pg/mL); and 25 (OH) vitamin D
level was within normal limits at 25 ng/mL (normal range, 9-52
ng/mL).
Technitium-99 sestamibi radionucleotide scanning revealed a
focus of increased activity in the right midchest corresponding to
the lung mass (Figure 1) and a
positron emission tomography
scan demonstrated no meta-
static disease (Figure 2). The
patient was thus taken to the
operating room, where an un-
complicated right upper lobec-
tomy was performed to remove
the mass.
Final pathology revealed a T2 N0 M0, 3.5-cm-margin, nega-
tive, moderately differentiated adenocarcinoma of the right upper
lobe. Serum PTH level drawn 1 day postoperatively decreased to
26 pg/mL, and the patient’s serum calcium level stabilized at 9.7
mg/dL. The patient returned to her preoperative state and has no
evidence of recurrence or hypercalcemia 24 months after resection.
Discussion
Humoral hypercalcemia of malignancy is defined as hypercalce-
mia induced by ectopic production of hormonal factors by neo-
plastic cells. The syndrome was proposed by Fuller Albright in
1941.4 In Albright’s description of a 51-year-old man with renal
carcinoma and hypercalcemia, he speculated that the coexistence
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Figure 1. Technitium-99 sestamibi radionucleotide scan demon-
strating a small focus of increased activity in the posterior
portion of the right midchest corresponding with the pulmonary
lesion (arrow). Radiotracer uptake is also present in 3 foci of the
neck. The multiplanar spectrum imaging of the neck and upper
chest seen here was obtained by using intravenous injection of
technetium-99M sestamibi cardiolite.
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of hypophosphatemia was due to ectopic production of PTH by the
tumor. Since then, humoral hypercalcemia of malignancy has be-
come a well-recognized cause of tumor-induced hypercalcemia that is
prevalent in pulmonary neoplasms. Although Albright was correct in
suggesting that a humoral factor could account for hypercalcemia,
most contemporary studies have identified parathyroid-related pro-
tein to be the factor chiefly responsible for hypercalcemia of
malignancy.
It is quite rare, in fact, to find a primary tumor that generates a
hypercalcemic state through the ectopic production of native PTH.
Our own review of the literature identified 8 such cases. These
included 3 primary bronchogenic tumors (1 squamous cell and 2
small cell),1-3 an ovarian tumor, a thymoma, a neuroectodermal
tumor, a thyroid adenocarcinoma, and a hepatocellular carcinoma.5
Consistent with the physiologic role of PTH, these patients gen-
erally present with increased serum calcium levels, low phospho-
rus levels, and high levels of 1,25 (OH) vitamin D.
The clinical, radiographic, and laboratory data presented here
support a ninth case of ectopic PTH secretion by a malignant
neoplasm. The patient presented with an increased serum calcium
level. Increased levels of 1,25 (OH) vitamin D; decreased levels of
25 (OH) vitamin D; and low phosphorous levels raised the suspi-
cion that PTH and not PTH-rp was responsible for the hypercal-
cemia. This was verified by means of laboratory analysis demon-
strating low levels of PTH-rp and increased levels of native PTH.
A neoplastic cause for the above findings was supported by the
substantial radiotracer uptake on sestamibi scanning favoring a
high level of metabolic activity in the mass (Figure 1). Perhaps the
most convincing data supporting native PTH production by the
mass was the dramatic reduction in PTH levels from 288 pg/mL to
24 pg/mL after surgical resection of the specimen.
Beyond reporting unusual pathology, the above case illustrates
how routine diagnostic workup of a common problem (hypercal-
cemia) can lead to unexpected results. One cannot assume that
hypercalcemia with increased PTH levels is parathyroid in nature
without proper investigation for potentially treatable malignant
neoplasms producing paraneoplastic syndromes.
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Figure 2. Positron emission tomographic scan demonstrating ra-
diotracer uptake within the right middle lung (arrow). No meta-
static foci are observed.
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